{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:40Z","timestamp":1788454840868,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The scale\u2010up of rifampicin\u2010based prevention regimens is an essential part of the global leprosy strategy. Daily rifampicin may reduce the effectiveness of the oral contraceptive pill (OCP), but little is known about the effects of rifampicin at the less frequent dosing intervals used for leprosy prophylaxis. As many women of reproductive age rely on OCP for family planning, evaluating the interaction with less\u2010than\u2010daily rifampicin regimens would enhance the scalability and acceptability of leprosy prophylaxis. Using a semi\u2010mechanistic pharmacokinetic model of rifampicin induction, we simulated predicted changes in OCP clearance when coadministered with varying rifampicin dosing schedules. Rifampicin given as a single dose (600 or 1200\u00a0mg) or 600\u00a0mg every 4\u00a0weeks was not predicted to result in a clinically relevant interaction with OCP, defined as a &gt;25% increase in clearance. Simulations of daily rifampicin were predicted to increase OCP clearance within the range of observed changes previously reported in the literature. Therefore, our findings suggest that OCP efficacy will be maintained when coadministered with rifampicin\u2010based leprosy prophylaxis regimens of 600\u00a0mg once, 1200\u00a0mg once, and 600\u00a0mg every 4\u00a0weeks. This work provides reassurance to stakeholders that leprosy prophylaxis can be used with OCP without any additional recommendations for contraception prevention.<\/jats:p>","DOI":"10.1002\/jcph.2303","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:07:15Z","timestamp":1688652435000},"page":"1283-1289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicted Pharmacokinetic Interactions Between Hormonal Contraception and Single or Intermittently Dosed Rifampicin"],"prefix":"10.1002","volume":"63","author":[{"given":"Kendra K.","family":"Radtke","sequence":"first","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences University of California San Francisco San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hill","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Foundation Technical Division The Hague The Netherlands"},{"name":"Centenary Institute University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schoenmakers","sequence":"additional","affiliation":[{"name":"Medical Technical Department NLR Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan","family":"Mulder","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Foundation Technical Division The Hague The Netherlands"},{"name":"Amsterdam Institute for Global Health and Development Amsterdam University Medical Centers Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"van der Grinten","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Foundation Technical Division The Hague The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Overbeek","sequence":"additional","affiliation":[{"name":"Medical Technical Department NLR Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Salazar\u2010Austin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Pediatric Infectious Diseases The Johns Hopkins University School of Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilcare","family":"de Medeiros Cordeiro Nascimento","sequence":"additional","affiliation":[{"name":"Erasmus MC Netherlands Institute for Health Sciences Erasmus University Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van Brakel","sequence":"additional","affiliation":[{"name":"Medical Technical Department NLR Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Weld","sequence":"additional","affiliation":[{"name":"Department of Medicine Divisions of Infectious Diseases and Clinical Pharmacology The Johns Hopkins University School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"United Nations Department of Economic and Social Affairs Population Division. Contraceptive Use by Method 2019: Data Booklet.UN;2019. doi:10.18356\/1bd58a10\u2010en"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-1143-4"},{"key":"e_1_2_9_5_1","unstructured":"World Health Organization.Global Tuberculosis Report 2020.World Health Organization;2020. Accessed November 25 2020.https:\/\/www.who.int\/publications\/i\/item\/9789240013131"},{"key":"e_1_2_9_6_1","unstructured":"World Health Organization.Guidelines for the Diagnosis Treatment and Prevention of Leprosy.World Health Organization. Regional Office for South\u2010East Asia;2018. Accessed July 14 2021.https:\/\/apps.who.int\/iris\/handle\/10665\/274127"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","unstructured":"World Health Organization.WHO Consolidated Guidelines on Tuberculosis: Module 1: Prevention: Tuberculosis Preventive Treatment.World Health Organization;2020.https:\/\/apps.who.int\/iris\/handle\/10665\/331170","DOI":"10.30978\/TB2021-2-86"},{"key":"e_1_2_9_8_1","unstructured":"United Nations General Assembly.Transforming Our World: The 2030 Agenda for Sustainable Development. Resolution Adopted by the General Assembly on 25 September 2015 (A\/RES\/70\/1).United Nations;2015. Accessed August 30 2021.https:\/\/sdgs.un.org\/2030agenda"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.747952"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2020.100007"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15027"},{"key":"e_1_2_9_12_1","volume-title":"Medical Eligibility Criteria for Contraceptive Use","author":"World Health Organization","year":"2015"},{"key":"e_1_2_9_13_1","volume-title":"WHO Operational Handbook on Tuberculosis. Module 1: Prevention \u2010 Tuberculosis Preventive Treatment","author":"World Health Organization","year":"2020"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003072"},{"key":"e_1_2_9_15_1","unstructured":"World Health Organization.Leprosy\/Hansen Disease: Contact Tracing and Post\u2010Exposure Prophylaxis.World Health Organization. Regional Office for South\u2010East Asia;2020. Accessed July 6 2021.https:\/\/apps.who.int\/iris\/handle\/10665\/336679"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3402-4"},{"key":"e_1_2_9_17_1","unstructured":"Dutch Trial Register.Stop the Transmission of Leprosy A cluster\u2010randomised controlled trial on post\u2010exposure chemoprophylaxis in contacts of persons affected by leprosy in 6 districts of India Indonesia and Brazil; 2018 April 12 [Accessed July 14 2023]. Available from:https:\/\/www.onderzoekmetmensen.nl\/en\/trial\/23060"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4649-0"},{"issue":"310","key":"e_1_2_9_19_1","article-title":"Protocol, rationale and design of BE\u2010PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post\u2010exposure prophylaxis of leprosy contacts","volume":"23","author":"Younoussa A","year":"2023","journal-title":"BMC Infect Dis"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1765"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70138-4"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009803801109"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(80)90034-7"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.92"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01733779"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746020-00003"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00353-10"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00210-17"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.1007"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01833-10"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa328"},{"key":"e_1_2_9_34_1","unstructured":"WaalewijnH.Adequate dolutegravir exposure dosed BID with rifampicin in children 6 to <18 years [Poster 847]. In:Conference on Retroviruses and Opportunistic Infections;2020.https:\/\/www.croiconference.org\/abstract\/adequate\u2010dolutegravir\u2010exposure\u2010dosed\u2010bid\u2010with\u2010rifampicin\u2010in\u2010children\u20106\u2010to\/"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01098-8"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.07.008"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201912-2489OC"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:30:24Z","timestamp":1697182224000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/jcph.2303"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2303","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"2023-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}